Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of
Lheureux, Stéphanie , Weberpals, Johanne I. , Hendrickson, Andrea E. Wahner , Olawaiye, Alexander , Mackay, Helen , Wilson, Michelle , Rodríguez-Freixinós, Víctor, Martín-Lorente, Cristina, Ward, Jacklyn, Chang, Karen, Wang, Lisa , Speers, Vanessa , Karakasis, Katherine, Bowering, Valerie , Chen, Alice P. , Fleming, Gini F. , Braña, Irene , Dhani, Neesha C. , Chang, Karen, Brenton, James D. , Oza, Amit M.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS5613-TPS5613

10.1200/jco.2015.33.15_suppl.tps5613 Get It

A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC).
Qin, Rui , Sicotte, Hugues , Carlson, Rachel E. , Tan, Winston , Jiménez, Rafael E. , Wang, Liewei , Eckel‐Passow, Jeanette E. , Costello, Brian A. , Pitot, Henry C., Dronca, Roxana , Wu, Kevin J. , Moynihan, Timothy J. , Atwell, Thomas D. , McMenomy, Brendan P., Kohli, Manish , Wang, Liguo , Quevedo, Fernando , Ho, Thai H. , Bryce, Alan H. , Dehm, Scott M.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 5056-5056

10.1200/jco.2015.33.15_suppl.5056 Get It

AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.
Hu, Brian , Fairey, Adrian, Madhav, Anisha, Li, Meng , Groshen, Susan , Stephens, Craig, Virk, Navneet, Martin, Sue Ellen , Erho, Nicholas , Jenkins, Robert B. , Xu, Tong , Xu, Yucheng, Goldkorn, Amir , Yang, Dongyun , Kim, Philip, Wang, Lina , Davicioni, Elai , Den, Robert B. , Gill, Inderbir S. , Quinn, David I

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e16092-e16092

10.1200/jco.2015.33.15_suppl.e16092 Get It

Comprehensive multiplatform biomarker analysis of 212 anal squamous cell carcinomas.
Wang, Jue , Arguello, David, Millis, Sherri Z. , Gatalica, Zoran , Hálfdánarson, Þorvarður R. , Halfdanarson, Thorvardur R , Boland, Patrick M. , Reddy, Sandeep K. , Meyer, Joshua E.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3519-3519

10.1200/jco.2015.33.15_suppl.3519 Get It

Plasma cell-free DNA-based prognosis in metastatic hormone sensitive prostate cancer.
Yadav, Siddhartha , Tan, Winston , Wang, Amy , Montesinos, Carlos, Wong, Calvin, Jia, Shidong , Yu, Jianjun , Yadav, Siddhartha , Kohli, Manish , Riaz, Irbaz Bin , Zheng, Tiantian , Du, Peter Pan

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: 242-242

10.1200/jco.2019.37.7_suppl.242 Get It

242 Background: We evaluated plasma cell free based genomic aberrations for prognosticating survival of newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) patients (pts). Methods: Plasma was collected from mHSPC pts enrolled between 2009-2014. Platelet poor plasma (PPP) fractions were processed uniformly and cell free DNA (cfDNA) extracted using Qiagen kits. Pts were followed after initiating hormonal therapy until death. Next Gen Sequencing (NGS) of cfDNA was performed using Illumina HiSeq X for a preselected panel of 128 genes (PredicineDDR-77 cancer driver genes; 29 genes in BRCA-FA homologous recombination deficiency (HRD) pathway; 22 DNA damage repair pathway genes). Statistical analyses of plasma genome based aberrations with overall survival (OS) were performed in R 3.5.1. Cox proportional-hazard models were used for survival analysis. Results: An average of 2.5 ml PPP from 99 pts yielded a median of 10.5 ng (range: 2.8-702) cfDNA per sample. 15/99 pt samples with a yield < 5 ng were excluded from sequencing; 9/99 samples failed NGS. Median follow-up time was 80.2 months (mths) (Range: 74.7, 87]); median OS was 69.1 mths (range: 54,NR). 29 pts with full NGS data had high volume metastatic disease. cfDNA yield correlated with metastatic volume (P = 0.01). Univariate analysis revealed both variables prognostic for OS (Metastatic volume: log-rank P=0.01, HR=2.1, 95% CI: 1.1-3.8; cfDNA yield: P =0.04, HR = 1.3, 95% CI: 1.03-1.7). Multivariate regression showed prognostic value of cfDNA yield remained independent of metastatic volume (P = 0.03, HR = 1.34, 95% CI: 1.02-1.76). 54/67 samples with NGS data had at least one mutation/copy number variation detected. Top mutated genes included TP53 (N=18), ATM (N=9), CHEK2 (N=7), FANCM (N=6), RB1 (N=6), BRCA2 (N=5), PIK3CA (N=4) and 37/67 pts harbored 1≥ variant in HDR pathways. These pts had a shorter survival (median: 58.6 mths) (P=0.04, HR= 2.28, 95% CI: 1.01-5.18) and pts with ATM mutations did significantly worse (median survival: 47.4 mths) (HR=4.03, P=0.0005, 95% CI: 1.73-9.37). Conclusions: Plasma cfDNA yield is prognostic for survival in newly diagnosed mHSPC state and presence of HRD pathway genomic aberrations in plasma cfDNA are associated with poor survival.
Activity of NEO2734, a novel dual inhibitor of both BET and CBP-P300, in SPOP-mutated prostate cancer.
Yan, Yuqian , Wang, Dejie , Pang, Xiaodong , Ma, Jian , Lin, Dong , Giles, Francis Joseph , Wang, Yuzhuo , Huang, Haojie

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: 62-62

10.1200/jco.2019.37.7_suppl.62 Get It

62 Background: We have previously reported that mutations in SPOP promote bromodomain and extra-terminal motif (BET) protein upregulation and BET inhibitor resistance in prostate cancer (Zhang et al., Nature Medicine 23(9):1055-1062, 2017). Other studies indicate that histone acetyltransferases (HATs) such as P300 are also upregulated in SPOP-mutated prostate cancer (Blattner et al., Cancer Cell 31: 436-451, 2017). Methods: We examined the anti-cancer effect of NEO2734 (Epigene Therapeutics Inc), a novel dual inhibitor of both BET and CBP-P300, in prostate cancer using cell line, organoid and patient-derived xenografts (PDX) as working models. We examined the anti-cancer effect of NEO2734 (Epigene Therapeutics Inc), a novel dual inhibitor of both BET and CBP-P300, in prostate cancer using cell line, organoid and patient-derived xenografts (PDX) as working models. Results: We demonstrated that while prostate cancer cell lines expressing F133V, the most frequent SPOP mutant, are very resistant to both BET inhibitor JQ1 and CBP/P300 inhibitor CPI-637, they are very sensitive to simultaneous cotreatment with JQ1 and CPI-637. Similarly, we demonstrated that F133V mutant cells are also very sensitive to NEO2734. We established PDX and organoid models from a patient with prostate cancer expressing a novel SPOP mutation Q165P. Computer simulation analysis reveals that the Q165P mutation causes larger conformational fluctuation, indicating that the structure of Q165P is less stable than that of wild type SPOP. Accordingly, co-immunoprecipitation assay showed that Q165P mutation impaired the dimerization ability of SPOP. We further showed that the Q165P mutant organoid was very sensitive to NEO2734 in vitro and the Q165P mutant PDX was very sensitive to NEO2734 in mice. Conclusions: These PDX-based pre-clinical studies indicate that the inhibition of both BET and CBP-P300, either by co-administration of two agents, or by treatment with the dual inhibitor, NEO2734, is effective in SPOP-mutated prostate cancer. These data provide a strong rationale for the inclusion of patients with SPOP-mutated prostate cancer in clinical studies of NEO2734.
Imaging in patients with severe mitral annular calcification: insights from a multicentre experience using transatrial balloon-expandable valve replacement
Praz, Fabien , Khalique, Omar , Lee, Raymond , Wu, Isaac Y. , Russell, Hyde M., Wang, Dee Dee , Veeragandham, Ramesh, Islam, Ashequl , Deaton, David W., Eudailey, Kyle W. , Akkoc, Deniz, Kantor, Alex , Wang, Catherine , Tang, Diane, Park, Joongheum S, Leung, Diana, Nazif, Tamim , Vahl, Torsten , Kodali, Susheel , Leon, Martin B. , Takayama, Hiroo , Bapat, Vinayak , Borger, Michael A. , Wang, Dee Dee , Praz, Fabien , Guerrero, Mayra , Kaneko, Tsuyoshi , Tang, Diane C H, Hahn, Rebecca T , George, Isaac , Takayama, Hiroo

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | March 6, 2019 | Volume: 20 | Issue: 12 | Pages: 1395-1406

10.1093/ehjci/jez050 | PMID 31220240 Get It

Abstract Aims To investigate valve sizing and the haemodynamic relevance of the predicted left ventricular outflow tract (LVOT) in patients with mitral annular calcification (MAC) undergoing transatrial transcatheter valve implantation (THV). Methods and results In total, 21 patients undergoing transatrial THV, multiplanar reconstruction (MPR), maximum intensity projection (MIP), and cubic spline interpolation (CSI) were compared for MA sizing during diastole. In addition, predicted neo-LVOT areas were measured in 18 patients and correlated with the post-procedural haemodynamic dimensions. The procedure was successful in all patients (100%). Concomitant aortic valve replacement was performed in eight patients (43%) (AVR group). Sizing using MPR and MIP yielded comparable results in terms of area, perimeter, and diameter, whereas the dimensions obtained with CSI were systematically smaller. The simulated mean systolic neo-LVOT area was 133.4 ± 64.2 mm2 with an anticipated relative LVOT area reduction (neo-LVOT area/LVOT area × 100) of 59.3 ± 14.7%. The systolic relative LVOT area reduction, but not the absolute neo-LVOT area, was found to predict the peak (r = 0.69; P = 0.002) and mean (r = 0.65; P = 0.004) post-operative aortic gradient in the overall population as well as separately in the AVR (peak: r = 0.91; P = 0.002/mean: r = 0.85; P = 0.002) and no-AVR (peak: r = 0.89; P = 0.003/mean: r = 0.72; P = 0.008) groups. Conclusion In patients with severe MAC undergoing transatrial transcatheter valve implantation, MPR, and MIP yielded comparable annular dimensions, while values obtained with CSI tended to be systematically smaller. Mitral annular area and the average annular diameter appear to be reliable parameters for valve selection. Simulated relative LVOT reduction was found to predict the post-procedural aortic gradients.
Quantitative phenotype analysis to identify, validate and compare rat disease models
Zhao, Yiqing , Smith, Jennifer R. , Wang, Shur‐Jen , Dwinell, Melinda R. , Shimoyama, Mary

Mayo Clinic

Database | March 5, 2019 | Volume: 2019 | Issue: No issue available | Pages: No page available

10.1093/database/baz037 | PMID 30938777 Get It

Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease
Schindler, Suzanne E. , Li, Yan , Todd, Kaitlin , Herries, Elizabeth, Henson, Rachel L. , Gray, Julia, Wang, Guoqiao , Graham, Danielle , Shaw, Leslie M. , Trojanowski, John Q. , Hassenstab, Jason , Benzinger, Tammie L.S. , Cruchaga, Carlos , Xiong, Chengjie , Chhatwal, Jasmeer P. , Noble, James M. , Ringman, John M. , Graff‐Radford, Neill R. , Ladenson, Jack H., Morris, John C. , Bateman, Randall J. , Fagan, Anne M. , Network, Dominantly Inherited Alzheimer, Fox, Nick C. , Cruchaga, Carlos , Bateman, Randall J , Xiong, Chengjie , Benzinger, Tammie L S , Fox, Nick C , Hassenstab, Jason , Morris, John C , Jucker, Mathias , Holtzman, David M. , Xiong, Chengjie , Network, Dominantly Inherited Alzheimer, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | March 4, 2019 | Volume: 15 | Issue: 5 | Pages: 655-665

10.1016/j.jalz.2018.12.019 | PMID 30846386 Get It

AbstractIntroductionFour less well‐studied but promising “emerging” cerebrospinal fluid (CSF) biomarkers are elevated in late‐onset Alzheimer disease (AD): neurogranin, synaptosomal‐associated protein‐25 (SNAP‐25), visinin‐like protein 1 (VILIP‐1), and chitinase‐3‐like protein 1 (YKL‐40).MethodsCSF neurogranin, SNAP‐25, VILIP‐1, and YKL‐40 were measured in families carrying autosomal‐dominant AD mutations.ResultsThe four emerging CSF biomarkers were significantly elevated in the mutation carriers (n = 235) versus noncarriers (n = 145). CSF SNAP‐25, VILIP‐1, and YKL‐40 were altered very early in the AD time course, approximately 15–19 years before estimated symptom onset. All CSF biomarkers predicted important AD‐related outcomes including performance on a cognitive composite, brain amyloid burden as measured by amyloid positron emission tomography, and the estimated years from symptom onset.DiscussionEarly abnormalities in CSF tTau, pTau, SNAP‐25, VILIP‐1, and YKL‐40 suggest that synaptic damage, neuronal injury, and neuroinflammation begin shortly after the commencement of brain amyloid accumulation.
A Systematic Review for Variables to Be Collected in a Transplant Database for Improving Risk Prediction
Almasri, Jehad , Tello, Mouaffaa, Benkhadra, Raed, Morrow, Allison S. , Farah, Wigdan , Álvarez‐Villalobos, Neri Alejandro , Mohammed, Khaled , Allen, Jay-Sheree , Kasiske, Bertram L. , Murad, M. Hassan , Hasan, Bashar , Alvarez Villalobos, Neri, Allen, Jay-Sheree P, Murad, Mohammad Hassan, Murad, M Hassan , Álvarez-Villalobos, Neri A , Hasan, Bashar , Prokop, Larry J. , Wang, Zhen , Israni, Ajay K. , Farah, Wigdan

Mayo Clinic

Transplantation | February 28, 2019 | Volume: 103 | Issue: 12 | Pages: 2591-2601

10.1097/tp.0000000000002652 | PMID 30768569 Get It

Background. This systematic review was commissioned to identify new variables associated with transplant outcomes that are not currently collected by the Organ Procurement and Transplantation Network (OPTN). Methods. We identified 81 unique studies including 1 193 410 patients with median follow-up of 36 months posttransplant, reporting 108 unique risk factors. Results. Most risk factors (104) were recipient related; few (4) were donor related. Most risk factors were judged to be practical and feasible to routinely collect. Relative association measures were small to moderate for most risk factors (ranging between 1.0 and 2.0). The strongest relative association measure for a heart transplant outcome with a risk factor was 8.6 (recipient with the previous Fontan operation), for a kidney transplant 2.8 (sickle cell nephropathy as primary cause of end-stage renal disease), for a liver transplant 14.3 (recipient serum ferritin >500 µg/L), and for a lung transplant 6.3 (Burkholderia cepacia complex infection for 1 y or less). OPTN may consider some of these 108 variables for future collection to enhance transplant research and clinical care. Conclusions. Evidence-based approaches can be used to determine variables collected in databases and registries. Several candidate variables have been identified for OPTN.